FLNA:BMV
Filana Therapeutics Inc
15,92 MXN
0,00%
(0,00) 1 d
5 oct, 12:05:31 GMT-6 · MXN
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de FLNA...
Cap. burs.
35,50 M
Vol. medio
0,00
Volumen
0,00
Máximo en 52 sem.
56,00 MXN
Mínimo en 52 sem.
15,92 MXN
N.º de empleados
19
Cap. burs.
35,50 M
Vol. medio
0,00
Volumen
0,00
Máximo en 52 sem.
56,00 MXN
Mínimo en 52 sem.
15,92 MXN
N.º de empleados
19
Noticias
De fuentes web y partners de noticias
www.dars.gov.et
·
hace 2 semanas
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss of $0.22 Per Share Beats Estimates, Shares Rise 8.92%
Perfil
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Acerca de Filana Therapeutics Inc